In particular, new therapeutic developments for immune resistant phenotypes, such as NSCLC with LKB1 and/or KEAP1 inactivation, are urgently needed to improve the extremely poor prognosis. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.